Evidence map›Paper›PMID 24786452›Full record

ArticleBlood2014

FDG/PET in CLL today.

Stefano Molica

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Association of [Diagnostics (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stefano MolicaAZIENDA OSPEDALIERA "PUGLIESE-CIACCIO"
Azienda Ospedaliera Pugliese Ciaccio · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Blood, Falchi et al present their experience with 2-deoxy-2-[18F] fluoroglucose/positron emission tomography (FDG/PET) in the management of patients with chronic lymphocytic leukemia (CLL) or Richter syndrome (RS) over a 10-year period at a referral center. The results of this study shed light on the potential role of FDG/PET in CLL.

Indexed as

Fluorodeoxyglucose F18Positron-Emission TomographyFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleFluorodeoxyglucose F18

Identifiers

PMID24786452
OpenAlexW1984406246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.